Company research

IDXX · NASDAQ

Idexx Laboratories Inc

Healthcare · Diagnostics & Research

$575.98

+2.32%

Close on Oct 29, 2026

Research data through 2026-10-29

Long-term research evidence only. No price targets, no trading signals, no recommendations.

Free research · no account required

Pro Investor Academy research

Research data through Oct 29, 2026. Research is updated periodically, not in real time.

Quality

76

of 100 · stored research reading

Stored Quality research reads 76 of 100, an above-average reading in the covered universe. Some underlying measurements are stronger than others.

Quality research measures durability of the business itself from stored fundamentals: balance-sheet strength, profitability consistency and cash generation. It is a research reading, not a prediction of future returns.

How this is measured

Fundamental Momentum

Accelerating

74

of 100 · stored research reading

Stored Fundamental Momentum research reads 74 of 100. Stored measurements classify recent reported fundamentals as accelerating. This describes reported financial change already disclosed, with no forward-looking claim.

Fundamental Momentum research measures the direction of recently reported company fundamentals compared with the company's own history. It describes reported change, not future price movement.

How this is measured

Capital Returns

Favorable

60

of 100 · stored research reading

Stored Capital Returns research reads 60 of 100, recorded as favorable. No dividend is recorded for this company, so the reading rests on buybacks and dilution control. Share count has been reduced at about 1.8% a year in the stored window.

Capital Returns research measures how a company has actually returned cash to shareholders: dividend record, buyback effectiveness, dilution control and how those payments were funded.

How this is measured

Valuation context

Price / earnings
38.8

Stored ratios recorded at the last research date (2026-10-27). Valuation Intelligence remains research context and is not a validated allocation signal.

Learn the basics of valuation

Investor intelligence

What Investor adds for IDXX

The research below is part of Investor membership. Values are withheld from this page entirely — nothing premium is loaded into it. Start the free trial and the intelligence you asked for unlocks right here.

Investor

See how this company ranks.

Unlock its Pro Investor Score and ranking across the research universe.

7 days · No credit card required

Investor

Understand the risk before you invest.

Unlock Risk Intelligence, Price Risk, and Market Confirmation.

7 days · No credit card required

Investor

Know why, not just what.

Unlock the Pro Research Brief with What Changed & Why, research history and tensions.

7 days · No credit card required

Investor

See what professional investors are reporting.

Unlock Pro Investor Intelligence: disclosed professional-manager and insider activity beside company research.

7 days · No credit card required

Investor

Ask the research.

Unlock Pro Investor AI to ask questions grounded in Pro Investor Academy research and evidence.

7 days · No credit card required

Investor

Keep researching after today.

Save companies and monitor how their research changes over time.

7 days · No credit card required

Explore other companies in this industry. These are objective industry neighbours, not suggested alternatives.

Want to know what qualified today?

Pro Investor Academy continuously applies its research rules across the eligible universe and surfaces a small number of investments for deeper research when they qualify.

Appears in

Rule-based membership

Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.

Learn the metrics on this page

Plain-English definitions, with the formula and the limitations of each measure.

In the company’s own words

What this company does

, Marketing and Distribution" included in this Annual Report on Form 10-K for additional information regarding distribution channels.

Effects of Patent Expiration . Although certain patents and licenses of patents and technologies from third parties periodically expire, the expiration of these patents or licenses, individually or in the aggregate, is not expected to have a material effect on our financial position or future operations due to a range of factors as described in "Part I, Item 1. Intellectual Property, Including Patents and License."

Non-GAAP Financial Measures . The following revenue analysis and discussion includes organic revenue growth, and references in this analysis and discussion to "revenue," "revenues," or "revenue growth" apply equally to revenue growth reported in accordance with U.S. GAAP and to "organic revenue growth." Organic revenue growth is a non-GAAP financial measure and represents the percentage change in revenue during the current year, compared to the same period for the prior year, net of the effect of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Organic revenue growth should be considered in addition to, and not as a replacement for, or as a superior measure to, revenue growth reported in accordance with U.S. GAAP, and may not be comparable to similarly titled measures reported by other companies. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers.

We exclude from organic revenue growth the effect of changes in foreign currency exchange rates because changes in foreign currency exchange rates are not under management’s control, are subject to volatility, and can obscure underlying business trends. We calculate the impact on revenue resulting from changes in foreign currency exchange rates by applying the difference between the weighted average exchange rates during the current period and the comparable prior year period to foreign currency denominated revenues for the prior year period.

Quoted from the business section of this company’s 10-K filed February 20, 2026. Read the filing

General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.